Pharmaceutical industry – Page 41
-
Business
AbbVie backs out of Shire deal
Treasury rule changes make inversion ‘too uncertain’ and remove financial benefits
-
Business
Endo outbids QLT for Auxilium merger
Biotech backs out of Canadian deal in favour of increased $2.6bn bid from Endo
-
Business
EMA finalises trial transparency rules
Researcher access reinstated, but company redaction rights may cause issues
-
Business
Actavis boosts antibiotics with Durata buyout
$820 million deal gives Actavis control of newly-approved intravenous antibiotic
-
Business
Becton Dickinson to buy CareFusion for $12bn
Medical devices merger continues consolidation trend
-
Business
J&J to buy antiviral specialist Alios
$1.75 billion deal brings Phase II compounds for hepatitis C and respiratory syncytial virus
-
FeatureTransparency measures forced on pharma
Previous misdemeanours are compelling the pharmaceutical industry to be more open with financial information and clinical data, writes Nuala Moran
-
Business
Lumara splits and sells to AMAG and Perrigo
Lumara has just emerged from bankruptcy and brings a drug for suppressing pre-term birth, plus other women’s health products
-
Business
India backs off drug pricing controls
Current price caps will stand, but rules on how new caps can be imposed are being tightened
-
-
Business
Review says cheaper drug is safe for eye disease
Cochrane collaboration says side effects of expensive Lucentis and off-label Avastin are similar
-
Business
Gilead licenses generic hepatitis C drug in India
Company aims to head off competition and grab a slice of royalties
-
Business
Pharma sales ‘will reach $1 trillion’ in 2014
Report predicts continued growth as sales reach an all-time high
-
Business
Cipla targets asthma market with Advair copy
Indian pharma company Cipla has launched a generic version of GSK’s best selling drug
-
Business
Servier to appear in adverts over lack of transparency
Adverts in the medical press will name French pharma firm for failing to comply with disclosure rules
-
Business
Piramal exits drug discovery in India
Company will concentrate on generic medicines and clinical and contract research.
-
Business
Novo Nordisk quits inflammation R&D and cuts jobs
Firm will return to primary focus on diabetes and obesity
-
Business
Exelexis slashes workforce by 70%
Poor clinical trial performance pushes company into cost-cutting drive
-
BusinessRoche to buy InterMune for respiratory boost
$8.3bn deal gives Roche a leading position in pulmonary fibrosis
-
Business
Clinical collaborations drive cancer immunotherapy
Companies race to pair up chemotherapy drugs with immune system-boosting antibodies to greatest effect in trials